Hormonal IUD and Bone Health: What Mirena and Kyleena Actually Do to Your Bone Density

Does the Hormonal IUD Affect Bone Density?

For most women in their reproductive years, the hormonal IUD does not cause clinically significant bone mineral density (BMD) loss. This is one of the clearest distinctions between the LNG-IUD and depot medroxyprogesterone acetate (Depo-Provera, DMPA), the injectable progestin that carries an FDA warning for bone loss. The difference comes down to one thing: estrogen.

DMPA suppresses ovulation so completely that it drives estradiol levels into the low range, sometimes below 30 pg/mL, a range that accelerates bone resorption. Research published in Obstetrics and Gynecology confirms this estrogen-suppression mechanism is the primary driver of DMPA-associated bone loss. The LNG-IUD works differently. It thickens cervical mucus, thins the endometrium, and may suppress ovulation partially, but systemic levonorgestrel absorption from Mirena averages only 14 micrograms per day in the first year, falling to roughly 8 micrograms per day after five years, according to Mirena prescribing information reviewed by the FDA. That low systemic level leaves most users with circulating estradiol in or near the normal follicular-phase range.

No bone loss in estrogen-replete women. That is the short version of the evidence.

Why This Matters More Than Most Guides Explain

Bone is not static. It remodels continuously, with osteoclasts resorbing old bone and osteoblasts laying down new matrix. Estrogen is the primary brake on osteoclast activity in women. When estrogen drops, the brake releases and resorption accelerates. Because the LNG-IUD preserves estrogen, the brake stays mostly engaged.

The practical takeaway: a 28-year-old with a Mirena inserted for heavy periods or contraception does not need to change her calcium intake, request a DXA scan, or worry that she is quietly losing bone. The perimenopausal woman at 49, however, is a different story, and her situation gets its own section below.

What the Data Actually Show

A 2006 prospective study in Contraception followed 44 women using the 52 mg LNG-IUS and found no significant change in lumbar spine or femoral neck BMD over two years. A systematic review in Human Reproduction Update (2010) examined multiple hormonal contraceptive methods and concluded that LNG-IUS use was not associated with BMD reduction, in direct contrast to DMPA. These findings are consistent across populations; women in their 20s, 30s, and early 40s show no clinically meaningful bone signal with the IUD.

How Levonorgestrel Differs From Other Progestins on Bone

Not all progestins behave the same way. This matters because some women, and some prescribers, assume "hormonal birth control" is a uniform category with uniform bone effects. It is not.

DMPA Versus the LNG-IUD

Depot medroxyprogesterone acetate carries an FDA black-box warning stating that its use may cause significant loss of BMD, that loss is greater with longer duration, and that it may not be completely reversible. A Cochrane review (Lopez et al., 2014) confirmed that DMPA users lose approximately 1.5 to 3 percent of lumbar spine BMD per year during use, with partial recovery after discontinuation. The LNG-IUD has no comparable warning and no comparable evidence for loss.

Norethindrone Acetate and Etonogestrel

Norethindrone-containing pills and the etonogestrel implant (Nexplanon) sit between DMPA and the LNG-IUD in terms of systemic progestin exposure and degree of ovulation suppression. Implant users have more systemic etonogestrel exposure than IUD users but far less than DMPA users, and the implant's bone data are mixed though generally reassuring. The LNG-IUD's bone profile remains the most favorable among progestin-dominant methods, specifically because of its limited systemic absorption.

Bone Health Across Life Stages: Where the Risk Actually Lives

This is the section that most articles skip. Bone risk from the LNG-IUD is not uniform across a woman's life. It depends almost entirely on her estrogen environment at the time of use.

Reproductive Years (Ages 18-44)

Bone risk is minimal. Ovarian estrogen production is largely intact. Studies consistently show no significant BMD change. A 2015 observational study in BJOG followed 196 LNG-IUS users for five years and found no difference in BMD compared to copper IUD users.

No DXA screening is recommended for healthy women in this age group who are using the LNG-IUD. Routine calcium (1,000 mg/day from food or supplements) and vitamin D (600 IU/day per NIH Office of Dietary Supplements recommendations) remain the standard of care regardless of contraceptive method.

Perimenopause (Roughly Ages 45-52)

This is where bone attention becomes relevant. In perimenopause, ovarian estrogen production becomes erratic and eventually falls. The LNG-IUD does not cause this decline, but it also does not prevent it. A woman who has a Mirena in situ for contraception and menopause symptom management during perimenopause may have declining estrogen despite the IUD, because the IUD's progestin does not replace estrogen.

ACOG Practice Bulletin 206 on the use of hormonal contraception in women with coexisting medical conditions notes that the LNG-IUD can be used safely in perimenopausal women. The key clinical point: if a perimenopausal woman using a Mirena is also experiencing hot flashes, night sweats, or genitourinary symptoms suggesting low estrogen, and she has other bone-risk factors (low body weight, smoking, family history of fracture, prior eating disorder, or long-term corticosteroid use), a baseline DXA scan becomes reasonable. The IUD itself is not the bone threat; the declining ovarian estrogen is.

Postmenopause and Mirena as the Progestin Arm of HRT

One of the least-discussed clinical uses of the Mirena is as the progestin component of menopausal hormone therapy. When a postmenopausal woman uses systemic estrogen (patch, gel, or spray) plus a Mirena, the IUD provides endometrial protection while delivering minimal systemic progestin. The British Menopause Society and Women's Health Concern have endorsed this "Mirena-plus-estrogen" approach as a valid regimen, noting it reduces the systemic progestin burden compared to oral or patch-combined HRT.

In this context, the bone effect is driven by the estrogen component, not the IUD. Estrogen therapy is one of the few interventions with Level I evidence for fracture prevention in postmenopausal women. The Women's Health Initiative (WHI) showed a 33 percent reduction in hip fracture risk with combined HRT. So when Mirena is part of a combined HRT regimen, it is contributing to bone protection indirectly by enabling estrogen use with endometrial safety.

Lactation and Postpartum Period

Breastfeeding itself suppresses estrogen significantly, and postpartum BMD loss during exclusive lactation can reach 3 to 5 percent at the lumbar spine, per a review in the Journal of Clinical Endocrinology and Metabolism. This loss is transient and largely recovers after weaning. The LNG-IUD inserted postpartum does not add meaningfully to this lactation-associated bone loss. ACOG supports immediate postpartum IUD insertion (within 10 minutes of placental delivery) as safe and effective.

Heavy Menstrual Bleeding, the LNG-IUD, and an Indirect Bone Benefit

The NEJM 2013 trial by Gupta and colleagues randomized 571 women with heavy menstrual bleeding to either the levonorgestrel IUS or usual medical care (which included combined oral contraceptives, norethindrone, or tranexamic acid). At 2 years, the LNG-IUS group had a significantly greater reduction in menstrual bleeding and better quality of life scores than the usual-care group, with 64 percent of IUS users reporting no clinically significant heavy bleeding at 24 months versus 14 percent in the usual-care group.

Why does this connect to bone health? Heavy menstrual bleeding sufficient to cause iron-deficiency anemia is associated with reduced physical activity, fatigue, and in severe cases, nutritional compromise, all of which can indirectly affect bone accrual and maintenance. Treating HMB effectively with the LNG-IUS may remove these indirect contributors to poor bone health, particularly in adolescents and young women still building peak bone mass.

A practical clinical framework for the bone-conscious woman considering the LNG-IUD:

1. No additional bone risk if you are in reproductive years with normal estrogen and no baseline bone-risk factors. Use it freely.
2. Reassess estrogen status if you are perimenopausal and symptomatic. The IUD does not raise or lower your estrogen; your ovaries do. Address estrogen separately if indicated.
3. Use it as HRT infrastructure if you are postmenopausal and on systemic estrogen. The Mirena eliminates the need for systemic progestogen while providing endometrial protection, which may actually reduce the cardiovascular and breast-tissue exposure concerns sometimes associated with oral progestins.
4. Do not conflate it with DMPA. If a prior provider warned you about bone loss "from hormonal contraception," ask specifically which method they meant. The LNG-IUD and DMPA are pharmacologically distinct in their bone effects.

Pregnancy, Lactation, and Contraception Requirements

The LNG-IUD is a contraceptive device. Pregnancy while an IUD is in situ is uncommon (failure rate approximately 0.1 to 0.8 percent per year depending on device type), but it carries serious risks.

Pregnancy While the IUD Is in Place

If pregnancy occurs with the IUD in place, there is an increased risk of ectopic pregnancy (approximately 50 percent of IUD failures are ectopic, per FDA labeling). Intrauterine pregnancy with the device in situ carries risk of septic abortion, preterm labor, and second-trimester pregnancy loss. If the strings are visible, the IUD should be removed; if not visible, imaging is needed. The device is contraindicated during confirmed pregnancy.

Levonorgestrel is a Category X-adjacent agent in the context of confirmed intrauterine pregnancy with device in place. While low-dose systemic LNG from an IUD is not associated with fetal teratogenicity in pregnancies that continue, the mechanical risks of leaving the device in situ are substantial. ACOG recommends attempting removal if strings are accessible.

Lactation Safety

The LNG-IUD can be inserted immediately postpartum or at the 4 to 6 week visit. Small amounts of levonorgestrel transfer to breast milk, but the World Health Organization Medical Eligibility Criteria for Contraceptive Use (WHO-MEC) categorizes the progestogen-only IUD as Category 1 (no restriction) for breastfeeding women more than 4 weeks postpartum, meaning it is safe to use. No adverse effects on infant growth or development have been demonstrated.

Bone considerations during lactation: the LNG-IUD does not protect against lactation-related BMD loss, which is driven by prolactin-mediated estrogen suppression and parathyroid hormone-related protein (PTHrP) from the breast. This is expected, normal, and reversible. The IUD does not worsen it.

Return to Fertility

Fertility returns promptly after IUD removal, typically within one to two menstrual cycles. Unlike DMPA, there is no prolonged delay in ovulation resumption. A prospective cohort study in Fertility and Sterility found that 80 percent of former LNG-IUS users who wanted to conceive had done so within 12 months of removal, a rate comparable to copper IUD users.

Who the LNG-IUD Is and Is Not the Right Choice For, by Life Stage and Condition

Well-Suited For

Reproductive-age women with PCOS. The LNG-IUD provides reliable contraception and endometrial protection against hyperplasia from anovulatory cycles without meaningfully affecting androgen or estrogen levels. ACOG Practice Bulletin 194 on PCOS notes the LNG-IUS as an appropriate option for endometrial protection.

Women with endometriosis. The Mirena reduces endometrial lesion activity and dysmenorrhea. A Cochrane review by Abou-Setta et al. found LNG-IUS use after surgical treatment of endometriosis reduced pain recurrence.

Perimenopausal women needing contraception. The LNG-IUD is effective for contraception (a requirement until 12 months after the final menstrual period per standard guidance) and may reduce heavy or irregular perimenopausal bleeding. The Menopause Society (formerly NAMS) supports continued LNG-IUS use into menopause transition.

Postmenopausal women on systemic estrogen therapy. The Mirena 52 mg provides licensed endometrial protection when used with systemic estrogen in women with a uterus, reducing the need for oral progestogen and potentially improving HRT tolerability.

Women with a history of eating disorders or low bone mass. Because the LNG-IUD does not reduce estrogen, it is a preferred contraceptive over DMPA in women who already have compromised bone density, per clinical consensus.

Requires Extra Conversation

Women with unexplained BMD reduction already documented on DXA. The IUD itself is unlikely to cause further harm, but the underlying cause of low BMD should be investigated before assuming bone health is stable.

Women on long-term corticosteroids. Steroids independently cause bone loss. Adding any hormonal contraceptive that preserves estrogen is preferable to DMPA in this group. The IUD is reasonable, but a baseline DXA and bone-protective strategy (adequate calcium, vitamin D, possible bisphosphonate) should be addressed as part of overall care.

Adolescents. Peak bone mass accrual continues through the mid-20s. The LNG-IUD is generally considered safe for adolescents, and the American Academy of Pediatrics and ACOG both support LARC methods including the LNG-IUD as first-line options for adolescents. Given the absence of evidence for BMD loss with the IUD and the well-established bone concerns with DMPA, the IUD is the preferable hormonal option in teens who want the lowest bone risk.

What to Ask Your Clinician and When to Get a DXA Scan

Most women using the LNG-IUD do not need a DXA scan. Period. Here are the situations where requesting one is reasonable:

• You are in the perimenopause or postmenopause transition and have two or more of the following: smoking, low body weight (BMI <18.5), family history of hip fracture, prior fragility fracture, or long-term corticosteroid use.
• You had a prior eating disorder that may have compromised peak bone mass.
• You are being evaluated for secondary amenorrhea from causes other than the IUD (hypothalamic amenorrhea, premature ovarian insufficiency).
• Your clinician is considering a DMPA-to-LNG-IUD switch specifically because of bone concerns, and you want a baseline to confirm recovery.

The International Society for Clinical Densitometry (ISCD) recommends DXA in premenopausal women only when specific risk factors for secondary osteoporosis are present, not for routine hormonal contraceptive use.

The Evidence Gap: What We Still Do Not Know

Women are underrepresented in long-term bone trials focused on contraceptives. Most LNG-IUD bone studies are small (under 200 participants), run for two to five years, and do not follow women who started the IUD in their teens through menopause. We have no long-term fracture-outcome data specific to the LNG-IUD. All bone-health conclusions are based on surrogate outcomes (DXA-measured BMD), not on fracture incidence.

The extrapolation from "no BMD loss on DXA" to "no increased fracture risk" is reasonable but not directly proven in LNG-IUD users specifically. The data are reassuring, and the pharmacological rationale is sound. But women deserve to know the distinction between "no signal in the available data" and "definitively proven safe for bone at every life stage for every duration of use."